Suppr超能文献

雾化治疗应用于慢性阻塞性肺疾病急性加重期的疗效比较:一项随机对照试验

Comparison of the effectiveness of nebulizer treatment applications in acute exacerbation of chronic obstructive pulmonary disease: a randomized controlled trial.

作者信息

Kerget Buğra, Tekin Erdal, Çil Gizem, Çelik Kadir, Aksakal Alperen

机构信息

Ataturk University, School of Medicine, Department of Pulmonary Diseases - Erzurum, Turkey.

Ataturk University, School of Medicine, Department of Emergency Medicine - Erzurum, Turkey.

出版信息

Rev Assoc Med Bras (1992). 2024 Dec 2;70(12):e20240861. doi: 10.1590/1806-9282.20240861. eCollection 2024.

Abstract

OBJECTIVE

In addition to oxygen support, bronchodilator therapy constitutes the most essential treatment step in patients with chronic obstructive pulmonary disease. Our study aimed to compare the effectiveness of nebulizer treatments in patients who presented to the emergency department with acute exacerbation of chronic obstructive pulmonary disease.

METHODS

Our study included 60 Group E chronic obstructive pulmonary disease patients admitted to the emergency department due to acute exacerbation of chronic obstructive pulmonary disease between June and September 2023 (NCT: 06178068). Patients were randomized as follows: Group 1: jet nebulizer treatment; Group 2: dry air nebulizer treatment; and Group 3: classic nebulizer treatment.

RESULTS

While an increase in forced vital capacity (FVC) and forced expiratory volume 1 (FEV1) levels was observed in Group 1 patients (in the order of p=0.009 and 0.007), a decrease in residual volume (RV) and total lung capacity (TLC) levels was observed (p=0.02 and 0.05, respectively). At the same time, an increase in FEV1 levels was observed in Group 2 and 3 patients (p=0.04 and 0.04, respectively). A decrease was observed in RV and TLC levels (p=0.02, 0.05, 0.02, and 0.04, respectively). When comparing the respiratory function test parameters at the beginning and on the fifth day of treatment, FEV1 and peak expiratory flow 25/75 (PEF25/75) levels were higher in Group 1 patients than in Group 2 and 3 patients (p=0.01 and 0.02, respectively).

CONCLUSION

In chronic obstructive pulmonary disease patients, jet nebulizer treatment is more effective regarding bronchodilator activity than other nebulizer treatments. However, dry air nebulizer treatment may be preferred in chronic obstructive pulmonary disease patients because it is easily applicable and sterilizable.

摘要

目的

除氧疗支持外,支气管扩张剂治疗是慢性阻塞性肺疾病患者最基本的治疗步骤。我们的研究旨在比较雾化治疗对因慢性阻塞性肺疾病急性加重而就诊于急诊科患者的有效性。

方法

我们的研究纳入了2023年6月至9月期间因慢性阻塞性肺疾病急性加重而入住急诊科的60例E组慢性阻塞性肺疾病患者(NCT:06178068)。患者被随机分组如下:第1组:喷射雾化器治疗;第2组:干空气雾化器治疗;第3组:传统雾化器治疗。

结果

第1组患者的用力肺活量(FVC)和第1秒用力呼气容积(FEV1)水平升高(p值依次为0.009和0.007),同时残气量(RV)和肺总量(TLC)水平降低(分别为p=0.02和0.05)。同时,第2组和第3组患者的FEV1水平升高(分别为p=0.04和0.04)。RV和TLC水平降低(分别为p=0.02、0.05、0.02和0.04)。在比较治疗开始时和治疗第5天时的呼吸功能测试参数时,第1组患者的FEV1和呼气流量峰值25/75(PEF25/75)水平高于第2组和第3组患者(分别为p=0.01和0.02)。

结论

在慢性阻塞性肺疾病患者中,喷射雾化器治疗在支气管扩张活性方面比其他雾化治疗更有效。然而,干空气雾化器治疗因其易于应用和可消毒,可能更受慢性阻塞性肺疾病患者青睐。

相似文献

本文引用的文献

1
Nebuliser therapy in critical care: The past, present and future.重症监护中的雾化治疗:过去、现在与未来。
J Intensive Care Soc. 2024 Feb;25(1):78-88. doi: 10.1177/17511437231199899. Epub 2023 Sep 20.
3
GOLD 2023 streamlines pharmacological treatment.
Eur Respir J. 2023 Sep 9;62(3). doi: 10.1183/13993003.01335-2023. Print 2023 Sep.
4
GOLD 2023 Update: Implications for Clinical Practice.GOLD 2023 更新:对临床实践的影响。
Int J Chron Obstruct Pulmon Dis. 2023 May 5;18:745-754. doi: 10.2147/COPD.S404690. eCollection 2023.
6
GOLD COPD report: 2023 update.慢性阻塞性肺疾病全球倡议(GOLD)报告:2023年更新版。
Lancet Respir Med. 2023 Jan;11(1):18. doi: 10.1016/S2213-2600(22)00494-5. Epub 2022 Nov 30.
8
Nebulized Therapies in COPD: Past, Present, and the Future.雾化治疗在 COPD 中的应用:过去、现在和未来。
Int J Chron Obstruct Pulmon Dis. 2020 Jul 12;15:1665-1677. doi: 10.2147/COPD.S252435. eCollection 2020.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验